I don’t think yesterday’s PR is going to get institutional biotech investors off the sidelines. There have been and continue to be many reasons to be skeptical of Anavex, starting with Missling himself. We’ll know with the next round of 13-F filings whether institutional investors (real ones, not index funds) are getting into the stock. So far (again excluding index funds), there has been zero interest.